India pharma and healthcare funding at $69.8M in July 2026

India’s pharma and healthcare sectors recorded total funding of $69.8 million across 18 rounds between July 01 and July 31, 2026, according to data from Tracxn. The data covers the HealthTech, Life Sciences and Healthcare sectors in India. Funding was 34.42 per cent lower than the previous month and 59.71 per cent lower than the same month last year. The previous month was June 01 to June 30, 2026, while the same month last year was July 01 to July 31, 2025. Stagewise funding in July comprised 12.3 per cent from seed-stage funding, 34.4 per cent from early-stage funding and 53.4 per cent from late-stage funding. Funding stood at $57.9 million in August 2025, $128.7 million in September, $159.7 million in October, $27.2 million in November and $162.1 million in December. In January 2026, funding stood at $222.0 million, followed by $50.5 million in February, $220.1 million in March, $291.5 million in April, $116.4 million in May, $106.5 million in June and $69.8 million in July. Iswarya Fertility Center accounted for a $37.0 million deal in July, followed by Arp at $10.0 million, Age Care Labs at $9.0 million, Supply6 at $5.0 million, V6 Clinics at $2.0 million, Mandrake Bio at $1.9 million and FibroHeal at $1.5 million. Unilever Ventures, Antler and Unicorn India Ventures were the most active VCs. Unilever Ventures participated in one round for Supply6, Antler participated in one round for Mandrake Bio, and Unicorn India Ventures participated in one round for Bioscan Research. The post India pharma and healthcare funding at $69.8M in July 2026 appeared first on Express Pharma.